马应龙八宝Mabo's品牌怎么样 申请店铺

我要投票 马应龙八宝Mabo's在眼霜行业中的票数:168 更新时间:2025-01-22
马应龙八宝Mabo's是哪个国家的品牌?「马应龙八宝Mabo's」是 马应龙药业集团股份有限公司 旗下著名品牌。该品牌发源于湖北武汉,由创始人陈平经过多年的不懈努力和高速发展,现已成为行业的标杆品牌。
马应龙八宝Mabo's怎么样

马应龙是一家经国家商务部认定的中华老字号企业,创始于公元1582年。经过多年持续快速健康发展,马应龙已经成为一家涉足于药品制造、药品研发、药品批发零售、连锁医院等多个领域的专业化多功能国际化的医药类上市公司。

公司与北京大学药学院、中国药科大学等多家科研机构建立了长期的战略合作关系。经国家人事部核准公司与北京大学共同组建了博士后工作站。2009年,马应龙药业集团股份有限公司技术中心被国家发改委、科技部等五部委认定为国家级企业技术中心,马应龙创新药物研发团队被湖北省委组织部认定为首批“湖北省重点产业创新团队”。

马应龙及旗下子公司分别通过了国家药监局GMP、GSP质量管理规范体系认证,获得国际权威机构SGS颁发的环境管理体系ISO14000和职业安全与健康管理体系OHSAS18000的认证,在医药行业内率先实现了“三认证”。在世界品牌实验室、世界经理人周刊联合评估的2009年“中国最具价值品牌500强”排行榜中,马应龙名列第213位,品牌价值达到了40.01亿元。2006年马应龙荣获国家工商总局认定的“驰名保护”。2009年,马应龙被中国非处方药物协会评选为“中国非处方药品牌企业十五强”

公司股票于2004年在上海证券交易所上市,由此获得了持续融资的通道和规范营运的平台。2007年,公司股票被上海证券交易所、中国证券指数公司选定为中国上市公司治理指数样本股,标志着公司治理水平获得社会公众、证券机构及专家的高度认可。

传承四百多年的历史文化,公司逐步形成了具有马应龙特色的企业文化体系。公司秉承“为顾客创造健康,为股东创造财富,为员工创造机会,为社会创造效益”的经营宗旨,倡导“以真修心,以勤修为”的哲学观,倡导“稳健经营、协调发展”的经营观,倡导“资源增值”的价值观,弘扬“龙马精神”的企业精神。马应龙将以实现中药现代化为己任,在品牌经营战略的指引下与时俱进,继往开来。


Ma Yinglong is a Chinese time-honored enterprise recognized by the Ministry of Commerce. It was founded in 1582 ad. After years of sustained, rapid and healthy development, Ma Yinglong has become a professional, multi-functional and international pharmaceutical listed company involved in drug manufacturing, drug research and development, drug wholesale and retail, chain hospitals and other fields. The company has established a long-term strategic cooperation relationship with many scientific research institutions, such as the school of pharmacy of Peking University and China Pharmaceutical University. With the approval of the Ministry of personnel of the people's Republic of China, the company and Peking University jointly set up a postdoctoral workstation. In 2009, the technology center of Ma Yinglong Pharmaceutical Group Co., Ltd. was recognized as a national enterprise technology center by five ministries and commissions including the national development and Reform Commission and the Ministry of science and technology, and the R & D team of Ma Yinglong innovative drugs was recognized as the first batch of "Hubei key industry innovation team" by the Organization Department of Hubei Provincial Committee. Ma Yinglong and its subsidiaries have respectively passed the GMP and GSP quality management standard system certification issued by the State Food and drug administration, obtained the certification of ISO14000 environmental management system and OHSAS18000 occupational safety and health management system issued by the international authoritative agency SGS, and took the lead in realizing the "three certifications" in the pharmaceutical industry. In the 2009 "top 500 most valuable brands in China" list jointly evaluated by world brand laboratory and World Manager weekly, Ma Yinglong ranked 213, with the brand value reaching 4.001 billion yuan. In 2006, Ma Yinglong was awarded "famous protection" by the State Administration for Industry and commerce. In 2009, Ma Yinglong was listed on Shanghai Stock Exchange in 2004 as one of the "top 15 Chinese over-the-counter drug brand enterprises" by China over-the-counter drug association, thus obtaining a channel for continuous financing and a platform for standardized operation. In 2007, the company's stock was selected as the sample stock of China's listed corporate governance index by Shanghai Stock Exchange and China Securities Index company, marking that the level of corporate governance was highly recognized by the public, securities institutions and experts. Inheriting more than 400 years of history and culture, the company has gradually formed a corporate culture system with Ma Yinglong's characteristics. The company adheres to the business tenet of "creating health for customers, creating wealth for shareholders, creating opportunities for employees and creating benefits for the society", advocates the philosophy of "cultivating the heart with sincerity, cultivating the mind with diligence", advocates the business concept of "stable operation and coordinated development", advocates the value concept of "resource added value", and promotes the enterprise spirit of "Longma spirit". Ma Yinglong will take the modernization of traditional Chinese medicine as his duty, keep pace with the times and carry forward the past and open up the future under the guidance of brand management strategy.

本文链接: https://brand.waitui.com/92904fecd.html 联系电话:86-27-87291519

千城特选小程序码

7×24h 快讯

英国政府借款大幅增加,遵守财政规则面临挑战

英国政府2024年12月预算赤字激增,在利率居高不下、经济增长疲软的情况下,英国政府在遵守财政规则方面面临挑战。英国国家统计局周三表示,12月政府支出超过收入178亿英镑(219.9亿美元),赤字比去年同期高出101亿英镑,远高于预算责任办公室预测的142亿英镑。推动这一增长的一个因素是利息支付,比2023年同期高出38亿英镑。(新浪财经)

8分钟前

策源资本旗下基金入股灵童机器人

36氪获悉,天眼查App显示,近日,灵童机器人(上海)有限公司发生工商变更,新增成都策源广益数字经济股权投资基金合伙企业(有限合伙)、成都高新策源共创企业管理咨询合伙企业(有限合伙)为股东,同时注册资本由103万人民币增至约115.9万人民币。灵童机器人(上海)有限公司成立于2022年8月,法定代表人为陆杰,经营范围含智能机器人的研发、智能机器人销售、服务消费机器人销售、人工智能硬件销售、人工智能应用软件开发、数字内容制作服务等。

8分钟前

百万tokens降价至0.8元后,豆包模型毛利率已能达到50%

从多个知情人士处获悉,豆包大模型去年大幅降价后,毛利率依然为正。其中,字节跳动最新推出的豆包大模型1.5,在推理成本优化上取得进一步突破。在火山引擎上售卖API的Doubao-1.5-pro,毛利率仍能达到50%。去年5月,字节跳动正式对外发布豆包大模型。其中,豆包通用模型pro-32k版,模型推理输入价格仅每百万tokens0.8元,而当时市场上同规格模型的定价一般为每百万tokens120元,是豆包模型价格的150倍。(界面)

8分钟前

华林证券:2024年净利同比预增973.03%—1288.62%

36氪获悉,华林证券发布业绩预告,预计2024年归母净利3.4亿元—4.4亿元,同比增长973.03%—1288.62%。公司持续推进科技金融转型战略,财富管理线上业务收入同比大幅增加。自营投资业务积极把握市场机遇,进一步提升配置资产能力,收入大幅增加。此外,公司针对红博会展信托受益权资产支持专项计划仲裁事项,于2023年度计提预计负债约2.28亿元,导致2024年度相关营业外支出同比大幅下降。该笔营业外支出为非经常性损益。

8分钟前

北京君羊商贸有限公司获千万级Pre-A轮融资

36氪获悉,近日,北京君羊商贸有限公司宣布获得腾信投资领投的Pre-A轮千万级融资。公司创始人邵群表示,本轮融资资金主要投入到开拓业务、技术创新和拓宽市场这三大核心领域,同时将投入大量资金用于AI 算法的优化和模型训练。

8分钟前

本页详细列出关于马应龙八宝的品牌信息,含品牌所属公司介绍,马应龙八宝所处行业的品牌地位及优势。
咨询